Horizon Therapeutics Public Limited Company

Symbol: HZNP

NASDAQ

116.3

USD

Market price today

  • 60.7368

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 26.63B

    MRK Cap

  • 0.00%

    DIV Yield

Horizon Therapeutics Public Limited Company (HZNP) Stock Price & Analysis

Shares Outstanding

229M

Gross Profit Margin

0.75%

Operating Profit Margin

0.14%

Net Profit Margin

0.12%

Return on Assets

0.05%

Return on Equity

0.09%

Return on Capital Employed

0.06%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO:Mr. Timothy P. Walbert
Full-time employees:2190
City:Dublin
Address:70 St. Stephen’s Green
IPO:2011-07-28
CIK:0001492426

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

General Outlook

In simple terms, Horizon Therapeutics Public Limited Company has 228.995 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.752% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.141%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.120%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.047% return, is a testament to Horizon Therapeutics Public Limited Company's adeptness in optimizing resource deployment. Horizon Therapeutics Public Limited Company's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.085%. Furthermore, the proficiency of Horizon Therapeutics Public Limited Company in capital utilization is underscored by a remarkable 0.061% return on capital employed.

Stock Prices

Horizon Therapeutics Public Limited Company's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $115.7, while its low point bottomed out at $115.19. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Horizon Therapeutics Public Limited Company's stock market.
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of Horizon Therapeutics Public Limited Company (HZNP) on the NASDAQ in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is 60.737 in 2023.

What is the ticker symbol of Horizon Therapeutics Public Limited Company stock?

The ticker symbol of Horizon Therapeutics Public Limited Company stock is HZNP.

What is company IPO date?

IPO date of Horizon Therapeutics Public Limited Company is 2011-07-28.

What is company current share price?

Current share price is 116.300 USD.

What is stock market cap today?

The market cap of stock today is 26632119430.000.

What is PEG ratio in 2023?

The current 0.000 is 0.000 in 2023.

What is the number of employees in 2023?

In 2023 the company has 2190.